AGENUS INC 8K

Agenus Inc. used its Form 8‑K to announce Q2 2026 results and a July 2026 $85 million private placement (with up to $255 million in related warrants) that will fund the Phase 3 ROBBIN trial of BOT+BAL in neoadjuvant MSS colon cancer, while reallocating resources from the BATTMAN trial and expanding BOT+BAL access programs.

On its Form 8‑K, Agenus Inc. reported second quarter 2026 financial results, described an oversubscribed July 2026 private placement that raised approximately $85 million upfront (with up to $255 million in additional milestone-aligned warrant proceeds) to fund the planned global Phase 3 ROBBIN trial of botensilimab plus balstilimab (BOT+BAL) in neoadjuvant MSS colon cancer, and outlined its strategy to prioritize resources toward this registrational program while expanding BOT+BAL access programs and discontinuing its funding commitment to the CCTG‑sponsored BATTMAN Phase 3 trial. The company highlighted strong neoadjuvant and advanced-disease clinical data supporting BOT+BAL, reported $34.5 million of Q2 2026 revenue (including $6.4 million in pre-commercial BOT+BAL product revenue from authorized access programs and $28.1 million in non‑cash royalty revenue), estimated a more than $7 billion U.S. annual sales opportunity for ROBBIN’s target population, and indicated that current financing is expected to fund ROBBIN initiation, regulatory alignment, and operations through at least Q3 2027, and potentially through year-end 2031 if all warrants are exercised.

Filing Facts

CIK

1098972

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-336780

Alert Tier

7